Experts remain that patients who have experienced trouble getting prescriptions filled switch to other similar amphetamine-based medications, according to The Washington Post.
Teva (NYSE:TEVA) recently disclosed that it could struggle to supply the drug for the next two to three months. However, the company is “producing and distributing as much as possible, as quickly as possible,” according to Teva spokesperson Kelley Dougherty.
Novartis (NYSE:NVS) subsidiary Sandoz has also acknowledged having a generic Adderall shortage. Sandoz is the second biggest manufacturer of the drug.
Bloomberg reported that Sandoz had supply problems with both the drug’s extended- and immediate-release versions.
DEA sets annual limits on sales of Adderall and generics each year. Those quotas have contributed to shortages of the drug in the past.
Some patients have had to wait multiple months to have prescriptions filled, according to Generics Bulletin.
Currently, seven out of nine manufacturers of the drug report Adderall shortages. The latest to join the list are Sun Pharma and Camber Pharmaceuticals.
According to ASHP, affected manufacturers did not provide a reason for the shortage.
In August, Teva reported a labor shortage on the packaging line for its 20-mg and 30-mg Adderall generic tablets.
FDA recently added Adderall generics to its database of drug shortages. The agency acknowledged Teva’s manufacturing delays as contributing to the shortage of the drug.
The FDA also cited an Adderall drug shortage occurring from September 2019 to 2022.
Demand for Adderall, which was first approved in 2001, has increased in recent years. Last year, there were 41 million prescriptions for the drug compared to 21.3 million in 2012, according to estimates from Symphony Health.
Adderall is a Schedule II drug and is commonly abused.
During the pandemic, a crop of Telehealth vendors began to exploit relaxed guidelines restricting mailing scheduled substances. The federal government is reportedly investigating two of those companies — Cerebral and Done — for possible violations of the Controlled Substances Act, according to The Wall Street Journal.
Earlier this year, FDA and DEA sent joint warning letters to owners of the websites kubapharm.com and premiumlightssupplier.com that claimed to sell Adderall and other medicines without a prescription.
This article was updated on October 13 with new information.